Heron Therapeutics (HRTX) Short Interest Ratio & Short Volume $1.87 -0.05 (-2.60%) Closing price 04:00 PM EasternExtended Trading$1.86 -0.02 (-0.80%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Heron Therapeutics Short Interest DataHeron Therapeutics (HRTX) has a short interest of 33.30 million shares. This marks a 1.03% increase in short interest from the previous month. The short interest ratio (days to cover) is 17.9, indicating that it would take 17.9 days of the average trading volume of 2.29 million shares to cover all short positions.Current Short Interest33,300,000 sharesPrevious Short Interest32,960,000 sharesChange Vs. Previous Month+1.03%Dollar Volume Sold Short$80.59 millionShort Interest Ratio17.9 Days to CoverLast Record DateApril 30, 2025Outstanding Shares152,564,000 sharesPercentage of Shares Shorted21.83%Today's Trading Volume946,733 sharesAverage Trading Volume2,294,882 sharesToday's Volume Vs. Average41% Short Selling Heron Therapeutics? Sign up to receive the latest short interest report for Heron Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartHRTX Short Interest Over TimeHRTX Days to Cover Over TimeHRTX Percentage of Float Shorted Over Time Heron Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202533,300,000 shares $80.59 million +1.0%N/A17.9 $2.42 4/15/202532,960,000 shares $63.28 million +1.4%23.0%19.9 $1.92 3/31/202532,520,000 shares $71.54 million +1.4%22.7%18.8 $2.20 3/15/202532,070,000 shares $74.40 million +2.4%22.4%17.5 $2.32 2/28/202531,330,000 shares $77.39 million +1.8%21.9%10.2 $2.47 2/15/202530,770,000 shares $54.77 million -0.2%21.5%10.7 $1.78 1/31/202530,840,000 shares $52.43 million -0.7%N/A10 $1.70 1/15/202531,060,000 shares $47.21 million +1.1%N/A10 $1.52 12/31/202430,710,000 shares $46.99 million +2.4%N/A9.9 $1.53 12/15/202429,980,000 shares $47.97 million +8.9%N/A9.6 $1.60 Get the Latest News and Ratings for HRTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/30/202427,540,000 shares $32.77 million -1.3%N/A8.8 $1.19 11/15/202427,910,000 shares $33.21 million -3.1%N/A15.3 $1.19 10/31/202428,810,000 shares $50.13 million -6.0%N/A15.7 $1.74 10/15/202430,640,000 shares $55.15 million -3.3%N/A14.9 $1.80 9/30/202431,700,000 shares $63.08 million -10.6%N/A14.4 $1.99 9/15/202435,440,000 shares $66.27 million -1.3%N/A14.9 $1.87 8/31/202435,920,000 shares $69.33 million -0.1%N/A15.5 $1.93 8/15/202435,960,000 shares $70.12 million +0.9%N/A14.9 $1.95 7/31/202435,630,000 shares $105.82 million -0.1%N/A14.9 $2.97 7/15/202435,660,000 shares $118.03 million +8.7%N/A14.7 $3.31 6/30/202432,820,000 shares $114.87 million +7.7%N/A14 $3.50 6/15/202430,470,000 shares $109.69 million +1.4%N/A14.5 $3.60 5/31/202430,040,000 shares $111.15 million -0.8%N/A12.3 $3.70 5/15/202430,270,000 shares $90.81 million +10.9%N/A12.6 $3.00 4/30/202427,290,000 shares $63.31 million +7.3%N/A11.6 $2.32 4/15/202425,430,000 shares $75.02 million -0.5%N/A9.8 $2.95 3/31/202425,550,000 shares $70.77 million +0.5%N/A8.8 $2.77 3/15/202425,430,000 shares $77.82 million +3.7%N/A8.4 $3.06 2/29/202424,530,000 shares $65.25 million -0.4%N/A8.8 $2.66 2/15/202424,620,000 shares $70.91 million +1.2%N/A8.4 $2.88 1/31/202424,330,000 shares $58.64 million +13.1%N/A6.6 $2.41 1/15/202421,520,000 shares $46.27 million +6.5%N/A6.5 $2.15 12/31/202320,210,000 shares $34.36 million -3.8%N/A6 $1.70 12/15/202321,000,000 shares $38.01 million -2.7%N/A6.8 $1.81 11/30/202321,580,000 shares $26.54 million +22.7%N/A7.4 $1.23 11/15/202317,590,000 shares $15.13 million -4.5%N/A6.4 $0.86 10/31/202318,410,000 shares $11.73 million -4.9%N/A9.1 $0.64 10/15/202319,360,000 shares $13.99 million -26.5%N/A8.9 $0.72 9/30/202326,330,000 shares $27.12 million +2.3%N/A12.8 $1.03 9/15/202325,750,000 shares $31.16 million +1.7%N/A13.4 $1.21Musk’s Project Colossus could mint millionaires (Ad)I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.All the details are waiting for you now — but you need to act before the May 1st funding window clos 8/31/202325,320,000 shares $41.52 million -8.8%N/A12.7 $1.64 8/15/202327,760,000 shares $46.50 million +14.2%N/A13.2 $1.68 7/31/202324,310,000 shares $40.35 million +9.4%N/A10.4 $1.66 7/15/202322,220,000 shares $28.22 million -1.0%N/A10.1 $1.27 6/30/202322,440,000 shares $26.03 million -2.0%N/A9.7 $1.16 6/15/202322,890,000 shares $29.99 million -2.1%N/A8.9 $1.31 5/31/202323,380,000 shares $26.65 million +8.0%N/A9 $1.14 5/15/202321,650,000 shares $28.79 million -2.9%N/A8.8 $1.33 4/30/202322,300,000 shares $53.30 million -3.8%N/A10.8 $2.39 4/15/202323,190,000 shares $63.31 million +0.2%N/A10.8 $2.73 3/31/202323,150,000 shares $34.96 million +1.5%N/A10.9 $1.51 3/15/202322,800,000 shares $53.81 million -2.0%N/A12.7 $2.36 2/28/202323,270,000 shares $55.15 million -11.0%N/A10.2 $2.37 2/15/202326,140,000 shares $68.75 million -2.4%N/A11.2 $2.63 1/31/202326,790,000 shares $72.60 million -1.0%N/A10.5 $2.71 1/15/202327,070,000 shares $85.81 million +8.2%N/A10.7 $3.17 12/30/202225,030,000 shares $62.58 million -13.2%N/A9.7 $2.50 12/15/202228,840,000 shares $73.25 million +2.2%N/A10.8 $2.54 11/30/202228,220,000 shares $76.48 million -0.6%N/A10 $2.71 11/15/202228,400,000 shares $90.88 million -1.3%N/A10.1 $3.20 10/31/202228,770,000 shares $110.76 million -1.4%N/A9.3 $3.85 10/15/202229,180,000 shares $107.09 million -12.7%N/A9 $3.67 9/30/202233,420,000 shares $141.03 million +2.1%N/A10.1 $4.22 9/15/202232,720,000 shares $159.35 million +0.2%N/A9.7 $4.87 8/31/202232,650,000 shares $133.54 million -4.0%N/A10.8 $4.09 8/15/202234,000,000 shares $182.58 million -15.9%N/A11.2 $5.37 7/31/202240,430,000 shares $112.40 million +0.6%N/A14.3 $2.78 7/15/202240,180,000 shares $118.13 million +10.3%N/A14.9 $2.94 6/30/202236,440,000 shares $101.67 million -6.5%47.0%13.8 $2.79 6/15/202238,980,000 shares $99.40 million +5.5%50.3%15.5 $2.55 5/31/202236,960,000 shares $121.97 million -0.1%N/A14.6 $3.30 5/15/202236,980,000 shares $132.76 million -0.1%N/A14.4 $3.59 4/30/202237,010,000 shares $167.29 million -0.5%N/A15.7 $4.52 4/15/202237,200,000 shares $218.36 million -5.3%N/A16.2 $5.87 3/31/202239,280,000 shares $224.68 million +16.0%N/A17.1 $5.72 3/15/202233,850,000 shares $163.83 million -2.6%N/A15 $4.84 2/28/202234,750,000 shares $246.73 million -1.4%N/A15.2 $7.10 2/15/202235,240,000 shares $311.52 million +1.7%N/A16.9 $8.84 1/31/202234,640,000 shares $301.71 million -6.3%N/A16.5 $8.71 1/15/202236,960,000 shares $321.55 million +0.9%N/A0 $8.70 12/31/202136,650,000 shares $334.61 million +7.9%N/A18.9 $9.13 12/15/202133,970,000 shares $306.41 million +8.1%N/A17.6 $9.02 11/30/202131,430,000 shares $297.01 million +2.1%N/A18.8 $9.45 11/15/202130,790,000 shares $336.53 million +3.6%N/A21.4 $10.93 10/29/202129,730,000 shares $327.33 million +5.2%N/A21.4 $11.01 10/15/202128,270,000 shares $299.38 million +5.1%N/A21.4 $10.59 9/30/202126,900,000 shares $287.56 million +2.0%N/A20.2 $10.69 9/15/202126,370,000 shares $307.47 million -3.1%N/A21.3 $11.66 8/31/202127,220,000 shares $317.66 million +5.9%N/A21.3 $11.67 8/13/202125,710,000 shares $284.10 million +0.1%N/A17.3 $11.05Think NVDA’s run was epic? You ain’t seen nothin’ yet (Ad)Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 7/30/202125,690,000 shares $317.53 million +5.9%N/A14 $12.36 7/15/202124,250,000 shares $317.43 million +2.2%N/A13.9 $13.09 6/30/202123,720,000 shares $368.13 million -1.4%N/A13.8 $15.52 6/15/202124,050,000 shares $372.05 million +1.6%N/A14.5 $15.47 5/28/202123,680,000 shares $314.23 million +11.8%N/A14.5 $13.27 5/14/202121,180,000 shares $329.03 million +0.8%N/A14.3 $15.54 4/30/202121,010,000 shares $370.20 million -1.9%N/A20.4 $17.62 4/15/202121,410,000 shares $369.75 million +1.5%N/A21.2 $17.27 3/31/202121,100,000 shares $322.83 million +2.7%N/A20.9 $15.30 3/15/202120,550,000 shares $348.12 million +2.0%N/A19 $16.94 2/26/202120,150,000 shares $363.71 million +2.2%N/A19.4 $18.05 2/12/202119,710,000 shares $364.83 million +3.0%N/A19.1 $18.51 1/29/202119,140,000 shares $351.41 million +7.8%N/A17.9 $18.36 1/15/202117,760,000 shares $325.72 million +1.3%N/A17.2 $18.34 12/31/202017,530,000 shares $372.86 million -0.4%N/A18.8 $21.27 12/15/202017,600,000 shares $316.10 million -5.2%N/A19.8 $17.96 11/30/202018,560,000 shares $333.89 million +2.5%N/A23 $17.99 11/15/202018,100,000 shares $328.15 million +3.6%N/A23.2 $18.13 10/30/202017,480,000 shares $280.38 million +0.5%N/A24.2 $16.04 10/15/202017,390,000 shares $272.85 million +2.0%N/A23.5 $15.69 9/30/202017,050,000 shares $252.68 million +10.5%N/A20.4 $14.82 9/15/202015,430,000 shares $238.86 million +0.8%N/A12.2 $15.48 8/31/202015,310,000 shares $218.93 million -6.0%N/A11.6 $14.30 8/14/202016,280,000 shares $252.50 million +1.5%N/A12.2 $15.51 7/31/202016,040,000 shares $261.29 million -5.3%N/A11.5 $16.29 7/15/202016,930,000 shares $277.65 million -9.9%N/A11.8 $16.40 6/30/202018,790,000 shares $276.40 million +10.2%N/A13.4 $14.71 6/15/202017,050,000 shares $326.68 million +2.6%N/A15.8 $19.16 5/29/202016,620,000 shares $306.14 million -0.2%N/A13.5 $18.42 HRTX Short Interest - Frequently Asked Questions What is Heron Therapeutics' current short interest? Short interest is the volume of Heron Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 33,300,000 shares of HRTX short. Learn More on Heron Therapeutics' current short interest. What is a good short interest ratio for Heron Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. HRTX shares currently have a short interest ratio of 18.0. Learn More on Heron Therapeutics's short interest ratio. Which institutional investors are shorting Heron Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Heron Therapeutics: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Heron Therapeutics' short interest increasing or decreasing? Heron Therapeutics saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 33,300,000 shares, an increase of 1.0% from the previous total of 32,960,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Heron Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Heron Therapeutics: 89bio, Inc. (11.86%), Ocular Therapeutix, Inc. (8.15%), Amphastar Pharmaceuticals, Inc. (9.22%), Aurinia Pharmaceuticals Inc. (9.26%), Wave Life Sciences Ltd. (8.59%), Gyre Therapeutics, Inc. (13.99%), Phibro Animal Health Co. (4.52%), Mineralys Therapeutics, Inc. (16.91%), Collegium Pharmaceutical, Inc. (14.75%), Syndax Pharmaceuticals, Inc. (25.17%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks. What does it mean to sell short Heron Therapeutics stock? Short selling HRTX is an investing strategy that aims to generate trading profit from Heron Therapeutics as its price is falling. HRTX shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Heron Therapeutics? A short squeeze for Heron Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of HRTX, which in turn drives the price of the stock up even further. How often is Heron Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including HRTX, twice per month. The most recent reporting period available is April, 30 2025. More Short Interest Resources from MarketBeat Related Companies 89bio Short Squeeze Ocular Therapeutix Short Squeeze Amphastar Pharmaceuticals Short Squeeze Aurinia Pharmaceuticals Short Squeeze Wave Life Sciences Short Squeeze Gyre Therapeutics Short Squeeze Phibro Animal Health Short Squeeze Mineralys Therapeutics Short Squeeze Collegium Pharmaceutical Short Squeeze Syndax Pharmaceuticals Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:HRTX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HRTX Stock Free HRTX Stock Alerts